Alternatively, we suggest using this opportunity to take a little break from work and read some of the interesting articles below. In some cases, they may not be available in every strength or form as the brand-name drug. Sulfasalazine methotrexate plaquenil rheumatoid arthritis Chloroquine autophagy mechanism Plaquenil overdose treatment Hydroxychloroquine deaths A recent case control study suggested a benefit of hydroxychloroquine HCQ in lowering the risk of cardiac manifestations of neonatal lupus cardiac-NL in pregnancies of anti-SSA/Ro positive patients with Systemic Lupus Erythematosus SLE. A historical. Objectives. Systemic lupus erythematosus SLE is a chronic autoimmune disease that primarily affects women of childbearing age. While the impact of hydroxychloroquine HCQ on SLE activity and neonatal lupus occurrence has been evaluated in several studies, its role on prematurity and intrauterine growth restriction IUGR remains uncertain. Hydroxychloroquine, also known as Plaquenil or HCQ, reduces the risk of atrial fibrillation for people with lupus by 67% according to a recent study. HCQ is a commonly-prescribed oral drug for systemic lupus erythematosus SLE. Hydroxychloroquine may be used as part of a combination therapy. Hydroxychloroquine is available as the brand-name drug Plaquenil. Generic drugs usually cost less than the brand-name version. Hydroxychloroquine and neonatal lupus Treating Lupus with Anti-Malarial Drugs Johns Hopkins Lupus Center, Hydroxychloroquine for the prevention of fetal growth. Plaquenil autoimmune neutropenia In 1941, discoid lupus patients were treated successfully with Atabrine, a compound developed in Germany in the 1920s. In the mid-1940s, both hydroxychloroquine HCQ and chloroquine CQ had been synthesized. In 1955 HCQ was shown to be effective for both systemic lupus and rheumatoid arthritis. Drug spotlight on hydroxychloroquine Lupus Foundation of America. Atrial Fibrillation, Hydroxychloroquine, and Lupus.. Prenatal exposure to hydroxychloroquine cuts risk of neonatal.. Cutaneous neonatal lupus cNL occurs in possibly 5-16% of anti-Ro±anti-La antibody exposed infants. Data suggest in utero exposure to hydroxychloroquine HCQ may prevent cardiac-NL. The aims were to assess whether in utero exposure to HCQ decreases. Objective. Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Hydroxychloroquine HCQ reduces disease activity and flares; however, pregnancy causes significant physiologic changes that may alter HCQ levels and lead to therapeutic failure. Therefore, our objective was to evaluate HCQ concentrations during pregnancy and relate levels to outcomes. Methods. The thymus may play a central role in the regulation of autoimmunity that drives the coexistence of systemic lupus erythematosus SLE and myasthenia gravis MG, as well as in treatment response of patients with both disorders, a case series suggests. This finding resulted from an analysis of.